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Epithelial-to-mesenchymal transition (EMT) has been implicated in various physiological and path-
ological events. In this study, we found that the synthetic glucocorticoid dexamethasone (Dex) can
inhibit transforming growth factor-beta1-induced EMT and cell migration. We also demonstrated
that Dex inhibits EMT through a mechanism involving the suppression of ROS generation. Surpris-
ingly, Dex alone induced mesenchymal-to-epithelial transition (MET). Dexamethasone treatment
abolished Snail1 binding to the E-cadherin promoter, suggesting that suppression of Snail1 contrib-
utes to the above roles of Dex. Our ﬁndings demonstrate that Dex functions as both a suppressor of
EMT and as an inducer of MET and therefore may be implicated in certain pathophysiological events.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Epithelial-to-mesenchymal transition (EMT) is a trans-differen-
tiation process by which epithelial cells lose their epithelial cell
characteristics and acquire a mesenchymal phenotype. EMT is
characterized by changes in cell morphology, the disruption of
tight junctions and adherent junctions, and decreased expression
of E-cadherin, zonula occludens-1 (ZO-1) and other molecules. In
addition, EMT is associated with increased expression of mesen-
chymal markers, such as ﬁbronectin and vimentin. EMT plays an
important role in embryogenesis, wound healing, tissue remodel-
ing, ﬁbrosis, and tumor metastasis [1,2]. The inverse process, mes-
enchymal-to-epithelial transition (MET), has also been implicated
in development and other biological events. However, very little
is known about the regulatory mechanisms underlying the MET.
The multifunctional cytokine transforming growth factor-b
(TGF-b) regulates cell proliferation, differentiation, migration,
extracellular matrix production, apoptosis and tumorigenesis [3].
TGF-b is also a potent inducer of EMT, and it has long been recog-
nized that through EMT induction, TGF-b can promote tumorchemical Societies. Published by E
forming growth factor-beta;
senchymal-to-epithelial tran-metastasis and invasion. Blockade of TGF-b signaling can decrease
tumor cell motility and metastasis [4].
A growing number of molecules have been found to be involved
in the EMT process. Among them, the zinc-ﬁnger transcription fac-
tor Snail, one member of the Snail superfamily of transcriptional
repressors, plays a major role in triggering EMT [5]. Ectopic expres-
sion of Snail suppresses E-cadherin expression, leading to a full
EMT phenotype, whereas silencing of Snail expression reverses this
process [6,7]. Snail expression has been detected in a number of
different human carcinoma and melanoma cell lines [8]. More
importantly, Snail is expressed at the invasive front of epidermoid
carcinomas and has been associated with breast carcinoma metas-
tasis [9]. These data support a key role for Snail as an inducer of tu-
mor metastasis.
Glucocorticoids are important signaling molecules involved in a
variety of physiological and pathological responses [10]. Synthetic
glucocorticoids are widely used drugs with broad anti-inﬂamma-
tory effects. The biological effects of glucocorticoids are mediated
by the glucocorticoid receptor (GR), a member of the nuclear
receptor superfamily [11,12]. The glucocorticoid receptor regulates
target gene expression through a glucocorticoid response element
(GRE)-dependent mechanism. Depending on the nature of the GRE,
glucocorticoid receptor binding can result in activation or
repression of genes containing GR-binding sites. Alternatively,
the glucocorticoid receptor can induce or suppress gene expressionlsevier B.V. All rights reserved.
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through protein–protein interactions of the glucocorticoid receptor
with other transcription factors. RU486 is a glucocorticoid antago-
nist that can compete with glucocorticoids and prevent glucocorti-
coid-receptor binding and is widely used in steroid hormone
research and for the treatment of Cushing’s syndrome [13].
The TGF-b and glucocorticoid signaling pathways interact both
positively and negatively. Glucocorticoids inhibit the TGF-b-
induced expression of extracellular matrix proteins, collagen, and
tissue inhibitors of metalloproteinases [14–16]. TGF-b has also
been shown to antagonize the effects of glucocorticoids during
wound healing and ﬁbrosis [17–19]. In addition, glucocorticoids
and TGF-b have been shown to have opposite effects on the regu-
lation of bone formation [20]. Conversely, TGF-b and glucocorticoid
signaling pathways interact positively in some processes [21–24].
However, it remains unclear whether glucocorticoid signaling is in-
volved in TGF-b-induced EMT.
2. Materials and methods
2.1. Cell culture and transfection
MvlLu cells (Mink lung epithelial cell line) were cultured in
MEM medium containing 10% FBS, penicillin (100 U/mL), strepto-
mycin (100 lg/mL) and non-essential amino acids. Cells were incu-
bated at 37 C in a humidiﬁed atmosphere of 5% CO2 until 30–50%
of conﬂuence was reached. Transfection was carried out using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions.
2.2. Cell lysate preparation and immunoblotting
Cells were lysed in lysis buffer containing 50 mmol/L HEPES (pH
7.4), 5 mmol/L EDTA, 50 mmol/L NaCl, 1% Triton X-100, 50 mmol/L
NaF, 10 mmol/L Na4P2O710H2O, 5 lg/mL aprotinin, 5 lg/mL leu-
peptin, 1 mmol/L Na3VO4, and 1 mmol/L phenylmethylsulfonyl
ﬂuoride (PMSF). Proteins (30 lg) were separated by SDS–poly-
acrylamide gel electrophoresis and transferred onto nitrocellulose
membranes. The membranes were subsequently blocked with 5%
skim milk and incubated with the indicated antibodies. Protein
bands were visualized using ECL reagents.
2.3. Measurements of cellular reactive oxygen species (ROS)
Cells were trypsinized, suspended in 1 mL of serum-free DMEM,
incubated with 10 lmol/L 20,70-dichloroﬂuorescein-diacetate
(DCFDA) at 37 C for 30 min, and then washed 3 times with ser-
um-free DMEM medium. DCFDA was excited at 488 nm, and ﬂuo-
rescence was measured at 525 nm with a ﬂow cytometer (Becton
Dickinson FACSCalibur). The mean ﬂuorescence per cell was used
for comparison.
2.4. Scratch assays
Conﬂuent monolayers of cells were scratched by a pipette tip
and further incubated with 10% FBS medium in the presence or ab-
sence of TGF-b1 for 48 h. Cell migration images were taken under a
microscope.
2.5. E-cadherin promoter analysis
The E-cadherin promoter luciferase reporter plasmid was a gen-
erous gift from Dr. Amparo Cano. Mv1Lu cells were seeded in 24-
well tissue culture plates and transiently transfected with human
E-cadherin promoter reporter and pRL-CMV Renilla reporter using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’sinstructions. Where indicated, cotransfections were carried out in
the presence of empty vector or human Snail1 expression plas-
mids. Twenty-four hours after transfection, cells were treated
with Dex or TGF-b1. Luciferase activities (ﬁreﬂy luciferase and
Renilla luciferase) were determined by a dual luciferase reporter
assay system (Promega). Luciferase activity was normalized to
E-cadherin promoter activity in control cells. All experimental
values were determined from triplicate wells.
2.6. Immunoﬂuorescence analysis of actin remodeling
Cells were grown on glass slides and treated with TGF-b1 and
Dex. To terminate the reactions, slides were quickly washed with
PBS followed by ﬁxing in 4% polyoxymethylene for 10 min. The
samples were stained with Texas red-phalloidin to visualize F-actin
and nuclei were stainedwith DAPI (blue ﬂuorescence). Imageswere
taken at 1000 magniﬁcation under a confocal microscope.
2.7. Antibodies and plasmids
Antibodies against the following were obtained: E-Cadherin (BD
Biosciences), Snail1 (Cell Signaling Technology), a-SMA (Millipore),
ﬁbronectin and Flag (Sigma), actin, glucocorticoid receptor, vimen-
tin and Cytokeratin 18 (Santa Cruz). Human Snail1 sequence was
cloned into the pCMV-Tag2B plasmid.
2.8. Chromatin immunoprecipitation (ChIP) assays
Chromatin preparation and ChIP experiments were performed
according to the protocol from Upstate Biotechnology. E-Cadherin
promoter was ampliﬁed with the primers described in Supplemen-
tary data. PCR was carried out according to the following program:
40 cycles at 94 C for 40 s, 62–65 C for 40s, and 72 C for 40s.
Ampliﬁed DNA was separated on a 2% agarose gel and visualized
with ethidium bromide.
2.9. Determination of Snail1 mRNA levels by reverse transcription-PCR
Total cellular RNAwas isolated using Trizol reagent according to
the manufacturer’s instructions. RNA was reverse transcribed and
ampliﬁed by PCR with the following primers described in Supple-
mentary data. The following PCR conditions were used for Snail1:
30 s at 94 C, 40 s at 60 C, and 30 s at 72 C. The ampliﬁcation prod-
ucts obtained in 35 cycles were analyzed on 2% agarose gels.
2.10. Materials
Dexamethasone (Dex), LY29402, SB203580 and RU486 were
purchased from Sigma. Compound C was from Calbiochem. NAC
and 20,70-dichloroﬂuorescein-diacetate (DCFDA) were from
Beyotime.
2.11. Statistical analysis
Data are expressed as means ± S.E.M. from at least three inde-
pendent experiments. Statistical analysis was performed using Stu-
dent’s t-test or one way ANOVA, followed by the LSD-t test for
multiple comparisons. P values < 0.05 were considered statistically
signiﬁcant.
3. Results
3.1. Dex inhibits TGF-b1-induced EMT and cell migration
Upon treatment with TGF-b1 (2 ng/mL), Mv1Lu cells acquired a
spindle-like cell morphology (Fig. 1A, upper panel), which is
Fig. 1. Dexamethasone (Dex) inhibits TGF-b1-induced EMT and cell migration. Mv1Lu cells were treated with TGF-b1 (2 ng/mL) for the indicated times. (A) EMT was assessed
by observing cell morphological changes under a phase-contrast microscope (top). The expression levels of EMT markers E-cadherin and ﬁbronectin were examined by
western blot (middle). To examine cell motility, conﬂuent Mv1Lu cells were scratched by a pipette tip and treated with TGF-b1 for 48 h in 10% FBS-containing medium. Cell
migration was observed under a phase-contrast microscope (bottom). (B) Cells were treated with TGF-b1 (2 ng/mL) and/or Dex (100 nM) for 48 h in 10% FBS-containing
medium, EMT was examined by examining the cell morphological changes (upper) and the expression levels of E-cadherin, a-SMA, vimentin, Cytokeratin 18 and ﬁbronectin
(lower) were determined. The effect of Dex (100 nM) on actin remodeling induced by TGF-b1 (48 h) was examined by immunoﬂuorescence (bottom). (C) Dose response of
Dex-induced inhibition of TGF-b1-induced EMT. Cells were treated with TGF-b1 (2 ng/mL) and the indicated doses of Dex. EMT was examined by cell morphological
phenotype (upper) and the levels of ﬁbronectin and E-cadherin (middle). Data are presented as means ± S.D. from at least three independent experiments. *P < 0.05, **P < 0.01.
(D) Cells were treated with or without TGF-b1 in the presence or absence of Dex (100 nM) as described above. Cell migration was determined by scratch assay.
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cadherin and upregulation of the mesenchymal marker ﬁbronectin
(Fig. 1A, middle panel). TGF-b1 also increased the motility ofMv1Lu cells as shown by a scratch assay (Fig. 1A, lower panel).
Interestingly, treatment of cells with the synthetic glucocorticoid
dexamethasone signiﬁcantly inhibited TGF-b1-induced EMT, as
Fig. 2. RU 486 reverses the inhibitory effect of dexamethasone (Dex) on TGF-b1-induced EMT and cell migration. (A) Mv1Lu cells were treated with TGF-b1 (2 ng/mL) for 48 h
in the presence of different concentrations of RU 486 and EMT was assessed by cell morphological changes and protein levels of E-cadherin. (B) Cells were treated with TGF-
b1 for 48 h in the presence or absence of 100 nM Dex and RU 486 (0.5 lM). EMT was assessed by observing cell morphological changes and E-cadherin protein levels. Cell
migration was measured by scratch assay (C).
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ment, and levels of E-cadherin, Cytokeratin 18, a-SMA, vimentin
and ﬁbronectin (Fig. 1B). Inhibition of EMT by Dex occurred in a
dose-dependent manner (Fig. 1C). Consistent with its effects on
EMT, Dex also inhibited TGF-b1-induced cell migration (Fig. 1D)
in scratch assays. In addition, Dex inhibited cell migration in the
absence of exogenous TGF-b1 (Fig. 1D). Interestingly, Dex had noeffect on the proliferation of Mv1Lu cells, but could block TGF-
b1-induced growth arrest (Fig. S1).
3.2. RU486 reverses the effect of Dex
To conﬁrm the speciﬁc effects of glucocorticoids on these phe-
notypes, a glucocorticoid receptor antagonist, RU 486, was used
Fig. 3. Dexamethasone (Dex) inhibits EMT by suppressing ROS generation. (A) Mv1Lu cells were treated with TGF-b1 (2 ng/mL) for the indicated times. The level of cellular
ROS was measured as described in Section 2. (B) NAC inhibits TGF-b1-induced EMT. Mv1Lu cells were treated with TGF-b1 for 48 h in the presence of 10 mmol/L NAC. EMT
was determined by cell morphological changes (upper) and expression of E-cadherin and ﬁbronectin (lower). (C) Dex inhibits TGF-b1-induced ROS generation. After
treatment with TGF-b1 (2 ng/mL) and/or Dex (100 nM) for 48 h, cells were washed 3 times with serum-free medium, incubated for 30 min with 10 lM DCFDA, washed again
3 times with serum-free medium and imaged by ﬂuorescence microscopy. (D) Cells were treated with TGF-b1 and/or Dex (100 nM) for the indicated times, and ROS
generation was measured as described in Section 2. Data are presented as means ± S.D. from at least three independent experiments. *P < 0.05, **P < 0.01. (E) Cells were
treated with TGF-b1 and/or 100 nM Dex for 48 h in the absence or presence of 0.3 mmol/L H2O2, and EMT was examined by observing cell morphological changes (upper) and
protein levels of E-cadherin and ﬁbronectin (lower).
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b1-induced EMT (Fig. 2A), although high doses of RU 486 (5–
10 lM) can induce cell phenotype changes and a decrease in E-cad-
herin. These changes may be due to non-speciﬁc effects, since high
concentrations of RU 486 can also lead to decreased cell growth. In
the presence of RU 486, Dex-mediated suppression of TGF-b1-in-
duced EMT was abolished, as shown by cell morphology and
expression of E-cadherin (Fig. 2B). RU 486 treatment also abolished
the Dex-mediated inhibition of cell migration (Fig. 2C). These re-
sults indicate that glucocorticoid has strong inhibitory effects on
TGF-b1-induced EMT and cell migration.
3.3. Dex inhibits EMT through suppression of ROS generation
Treatment of cells with TGF-b1 markedly increases the cellular
ROS level, as measured by DCFDA ﬂuorescence (Fig. 3A). N-Acetyl-
cysteine (NAC) is a powerful antioxidant that reacts with several
ROS. NAC can also suppress TGF-b1-induced ROS generation(Fig. S2). In the presence of NAC, TGF-b1-induced morphological
changes, the increase in ﬁbronectin, and the decrease in E-cadherin
were blocked (Fig. 3B). Interestingly, Dex can also signiﬁcantly sup-
press TGF-b1-induced ROS generation (Fig. 3C and D). Treatment
with H2O2, a well-known oxidant that can increase cellular ROS
levels, abolished the inhibitory effect of Dex on TGF-b1-induced
EMT (Fig. 3E), which conﬁrmed that Dex inhibits TGF-b1-induced
EMT through a mechanism involving the suppression of ROS.
Treatment with H2O2 alone did not induce EMT, suggesting that
ROS is necessary but not sufﬁcient to induce EMT.
3.4. Dex promotes MET
MET is the reverse process of EMT, and has been implicated in
embryonic development [25]. Surprisingly, we observed that Dex
not only blocked TGF-b1-induced EMT (Fig. 1), but also induced
MET. Cells that underwent EMT 48 h after TGF-b1 induction
(Fig. 4A) could be restored to their original epithelial phenotype
Fig. 4. Dexamethasone (Dex) promotes MET. After treatment with TGF-b1 (2 ng/mL) for 48 h, Mv1Lu cells acquired a mesenchymal phenotype (A). The mesenchymal-like
cells (in A) were treated with Dex (100 nM) for another 48 h in the presence of TGF-b1. MET was assessed by cell morphology (B, upper) and the levels of mesenchymal
markers ﬁbronectin and epithelial maker E-cadherin were determined by Western blot (B, lower). (C) Cells were treated with TGF-b1 (2 ng/mL) for 48 h to induce EMT. Then,
cells were treated with Dex (100 nM) for the indicated times in the presence of TGF-b1, and MET was determined by cell morphology. (D) RU 486 inhibits Dex-induced MET.
After treatment with TGF-b1 (2 ng/mL) for 48 h to induce EMT, cells were treated with Dex (100 nM) for an additional 48 h in the presence or absence of RU 486 (0.5 lM).
MET was assessed by observing cell morphological changes and the protein levels of E-cadherin and ﬁbronectin. (E) SB203580, LY294002, Compound C, TSA did not induce
MET. Mv1Lu cells were treated with TGF-b1 (2 ng/mL) for 48 h to induce EMT. Afterward, they were treated with SB203580 (10 lM), LY294002 (10 lM), Compound C
(10 lM), TSA (20 ng/mL) or Dex (100 nM) for 48 h in the presence of TGF-b1, and MET was assessed by cell morphology and levels of ﬁbronectin and E-cadherin.
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cell morphology and expression levels of E-cadherin and ﬁbronec-
tin. Dexamethasone-induced MET exhibited a typical time-depen-
dent progression (Fig. 4C). Furthermore, RU 486 treatment blocked
Dex-induced MET in the presence of TGF-b1 (Fig. 4D), supporting arole for glucocorticoids in the induction of MET. To determine
whether glucocorticoid promotes MET simply by virtue of inhibit-
ing EMT, we examined the effects of other EMT inhibitors on MET
induction: SB203580 (p38 inhibitor), LY294002 (PI3K inhibitor),
TSA (HDAC inhibitor), and Compound C (AMP-activated kinase
Fig. 5. Dexamethasone (Dex) promotes MET and inhibits EMT by blocking the inhibitory effect of Snail1 on E-cadherin promoter. (A) Dex increases E-cadherin promoter
activity during MET. Twenty-four hours after transfection of the luciferase reporter plasmid, Mv1Lu cells were treated with TGF-b1 (2 ng/mL) for 48 h to induce EMT. The EMT
cells were treated with 100 nM Dex for the indicated times in the presence of TGF-b1 and E-cadherin promoter activity was examined. Data are presented as means ± S.D.
from at least three independent experiments. **P < 0.01. (B) Dex stimulates E-cadherin promoter activity. Mv1Lu cells were treated with Dex for indicated times, and relative
E-cadherin promoter activity was examined. Data are presented as means ± S.D. from at least three independent experiments. **P < 0.01. (C) Dex induced MET (performed as
above). Snail1 mRNA levels were examined by RT-PCR. (D) ChIP assays showed that Dex impaired Snail1 binding to the E-cadherin promoter during MET and EMT. Upper
panel: cells were treated with TGF-b1 (2 ng/mL) for 48 h to induce EMT, and then treated with/without Dex (100 nM) for 48 h in the presence of TGF-b1. Lower panel: cells
were treated with TGF-b1 (2 ng/mL) for 48 h in the presence or absence of Dex (100 nM). ChIP assays were carried out using antibodies against Snail1 and IgG. (E) Dex
abolishes Snail1 overexpression-induced suppression of E-cadherin promoter activity. Twenty-four hours after transient transfection of Snail1, cells were treated with Dex for
the indicated times, and relative E-cadherin promoter activity was examined. (F) Dex inhibits Snail1-induced EMT. After transient transfection of Snail1, cells were treated
with/without 100 nM Dex for 48 h. EMT was assessed by cell morphological changes (upper panel) and the expression levels of E-cadherin (lower panel).
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TGF-b1-induced EMT (Fig. S3), they did not induce the MET
(Fig. 4E, upper and lower panels). Similar results were obtained
in cells co-treated with these inhibitors (Fig. S4).
3.5. Dex promotes MET and inhibits EMT by blocking the inhibitory
effect of Snail1 on the E-cadherin promoter
To investigate the mechanism by which Dex promotes MET, we
examined E-cadherin promoter activity. Dex could restore the
E-cadherin promoter activity of cells with a mesenchymal pheno-
type to the normal level of epithelial cells (Fig. 5A). Dex treatment
also abolished the inhibition of E-cadherin promoter activity byTGF-b1 during EMT (Fig. S5A). Moreover, Dex enhanced the
E-cadherin promoter activity in a time-dependent manner in nor-
mal Mv1Lu cells (Fig. 5B). Snail1 is a key regulatory molecule for
EMT that can bind to E-box elements of the E-cadherin promoter
and suppress E-cadherin transcription. Snail1 expression increases
during TGF-b1-induced EMT (Fig. S5B). The above results suggest
that suppression of Snail1 may play a role in this MET process.
Dex had no inhibitory effect on Snail1 mRNA levels during MET
(Fig. 5C), and did not block the TGF-b1-induced increase in Snail1
expression levels (Fig. S5C). Dex treatment (48 h) of cells that
have undergone EMT impaired the interaction of Snail1 with
the E-cadherin promoter during MET, as shown by ChIP assay
(Fig. 5D, upper panel). Dex also blocked Snail1 binding to the
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cluded the possibility that Dex inhibits the Snail–E-cadherin pro-
moter interaction by inducing glucocorticoid receptor binding to
the E-cadherin promoter. As shown in Fig. S6, the glucocorticoid
receptor did not interact with the E-cadherin promoter. Further-
more, Dex treatment also signiﬁcantly restored the E-cadherin
promoter activity that was suppressed by Snail1 overexpression
in Mv1Lu cells (Fig. 5E). These results demonstrate that blocking
Snail1 binding to the E-cadherin promoter contributes to the
Dex-mediated suppression of EMT and the induction of MET. To
conﬁrm this model, we generated a cell line transiently over-
expressing Snail1. Overexpression of Snail1 induced the morpho-
logical phenotype characteristic of EMT. Treatment of Snail1-
overexpressing cells with Dex completely restored the epithelial
phenotype as shown by cell morphology (Fig. 5F, upper) and
E-cadherin levels (Fig. 5F, lower).
4. Discussion
Glucocorticoids are among the most widely used anti-
inﬂammatory drugs for the treatment of inﬂammatory disorders
including rheumatoid arthritis, asthma, dermatitis, idiopathic
pulmonary ﬁbrosis and autoimmune diseases such as Crohn’s dis-
ease [10]. Here, we found that the synthetic glucocorticoid Dex can
block TGF-b1-induced EMT in Mv1Lu cells. Recently, Godoy et al.
reported changes in the mRNA levels of 12 of 17 analyzed EMT
markers in mouse primary hepatocytes in the presence of Dex
[30]. This ﬁnding suggested that Dex may be a potent regulator
of EMT, which is supported by our observations.
ROS are free radicals that contain an oxygen atom and include
hydrogen peroxide, superoxide anion and hydroxyl radical. Cellular
production of ROS has been implicated in various pathophysiolog-
ical processes, such as carcinogenesis [31] and ﬁbrotic diseases
[32]. ROS have been reported to play an important role in TGF-b in-
duced EMT [33,34]. In addition, ROS have also been shown to be in-
volved in the mediation of matrix metalloproteinase 3-, hypoxia-,
and aldosterone-induced EMT [35–37]. Suppression of cellular
ROS signaling with antioxidants, such as NAC, can inhibit TGF-b-in-
duced EMT [38]. In the current study, we have shown that Dex
inhibited TGF-b1-induced EMT by suppressing TGF-b1-induced
ROS generation. However, it remains unclear how glucocorticoids
could block such ROS generation. Dex may suppress TGF-b-induced
ROS generation by modulating mitochondrial function or the
expression levels of certain redox-oxidation enzymes.
A growing body of evidence has been obtained concerning the
mechanisms of EMT regulation. However, much less is known
about MET. Auersperg et al. reported that MET could be induced
by overexpression of the epithelial marker E-cadherin in cultured
cells [39]. Das et al. showed that complete reversal of EMT required
inhibition of both ZEB1 and Rho pathways [40]. Inhibition of p38
MAPK, PI3K, HDAC and AMP-activated kinase inhibited TGF-b-
induced EMT, but could not reverse EMT or induce MET. These
results indicate that inhibition of EMT alone is not sufﬁcient to in-
duce MET. Our novel ﬁnding that the glucocorticoid Dex can induce
MET presents an important step toward understanding the regula-
tion of MET.
The transcription factor Snail can suppress E-cadherin transcrip-
tion by recognizing E-box elements in its target promoters, and it
plays a critical role in EMT [6,7]. The ﬁnding that Dex stimulates
E-cadherin promoter activity is consistent with previous reports
that Dex can increase E-cadherin expression in human primary
nasal epithelial cells and human osteoblastic Cells [41,42].
E-Cadherin re-expression is required for MET, which indicates that
the suppression of Snail may be involved in Dex-mediated MET. In-
deed, Dex blocked the binding of Snail1 to the E-cadherin promoter,
which abolished the Snail1 overexpression-induced suppression oftranscriptional activity of E-cadherin, contributing to the inhibition
of EMT. These observations indicate that the same signaling compo-
nents can be utilized both in the inhibition of EMT and in the induc-
tion of MET. The precise mechanism by which glucocorticoids
inhibit Snail1 binding to the E-cadherin promoter has not yet been
determined. Dex may induce the interaction of Snail1 with speciﬁc
molecules that block E-cadherin promoter association. In addition,
Dex may inhibit Snail1 binding to E-cadherin promoter by blocking
the nuclear translocation of Snail1.
Inhibition of EMT is potentially of great importance in thera-
peutic practice, and the induction of MET may also be a promising
strategy for medical treatment. The present study suggests that in
the treatment of ﬁbrosis, glucocorticoids can act not only through
anti-inﬂammatory effects but also by inducing MET and inhibiting
EMT. EMT defects have been reported to be involved in the induc-
tion of cleft palate [43], and glucocorticoids have been shown to in-
duce cleft palate in mice [44–47]. Our data further suggest that
glucocorticoid-induced cleft palate may be related to its inhibitory
effect on EMT. It has been reported that Dex does not inhibit TGF-
b1-induced changes in the mRNA levels of E-cadherin and ﬁbro-
nectin, but is able to suppress the increase of a-SMA in human
bronchial epithelial cells [48]. The discrepancy between this report
and our observations may be due to tissue or cell type speciﬁcity.
In addition, mRNA levels may not correlate well with levels of pro-
tein molecules because the latter can be regulated at several differ-
ent levels.
In summary, our data show that the synthetic glucocorticoid
Dex inhibits TGF-b1-induced EMT and cell migration by suppress-
ing TGF-b1-induced ROS generation. H2O2, a well-known oxidant
that can increase cellular ROS, can block Dex-mediated suppres-
sion of EMT induced by TGF-b1. We have also demonstrated that
Dex can induce MET. Treatment with Dex blocks Snail1 binding
to the E-cadherin promoter, suggesting that suppression of Snail1
contributes to both the inhibition of EMT and the induction of
MET. Further studies in other cellular models are needed to deter-
mine the ubiquity of these processes in normal and pathological
processes.
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